ISRG

521.33

-0.67%↓

ABT

105.94

-0.95%↓

MDT

100.69

-0.6%↓

A

133.92

-1.3%↓

VEEV

216.71

-1.4%↓

ISRG

521.33

-0.67%↓

ABT

105.94

-0.95%↓

MDT

100.69

-0.6%↓

A

133.92

-1.3%↓

VEEV

216.71

-1.4%↓

ISRG

521.33

-0.67%↓

ABT

105.94

-0.95%↓

MDT

100.69

-0.6%↓

A

133.92

-1.3%↓

VEEV

216.71

-1.4%↓

ISRG

521.33

-0.67%↓

ABT

105.94

-0.95%↓

MDT

100.69

-0.6%↓

A

133.92

-1.3%↓

VEEV

216.71

-1.4%↓

ISRG

521.33

-0.67%↓

ABT

105.94

-0.95%↓

MDT

100.69

-0.6%↓

A

133.92

-1.3%↓

VEEV

216.71

-1.4%↓

Search

Johnson and Johnson

Aperta

SettoreSettore sanitario

226.93 0.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

224

Massimo

228.51

Metriche Chiave

By Trading Economics

Entrata

-385M

5.2B

Vendite

571M

25B

P/E

Media del settore

20.081

89.037

EPS

2.46

Rendimento da dividendi

2.33

Margine di Profitto

21.473

Dipendenti

138,100

EBITDA

-4.9B

4.4B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+7.49% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.33%

2.18%

Utili prossimi

14 apr 2026

Prossima data del Dividendo

10 mar 2026

Prossima data del' Ex Dividendo

24 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

6.8B

534B

Apertura precedente

225.99

Chiusura precedente

226.93

Notizie sul Sentiment di mercato

By Acuity

32%

68%

82 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 gen 2026, 16:07 UTC

Utili

Intuitive Surgical Stock Beats Earnings Estimates. The Stock Is Barely Moving. -- Barrons.com

23 gen 2026, 12:58 UTC

Utili

Intuitive Surgical Stock Rises on Earnings. What Wall Street Is Saying. -- Barrons.com

21 gen 2026, 19:24 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 gen 2026, 15:31 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 gen 2026, 12:07 UTC

Utili

Johnson & Johnson Earnings Beat Estimates. The Stock Is Falling. -- Barrons.com

21 gen 2026, 11:35 UTC

Utili

Johnson & Johnson Earnings Beat Estimates. The Stock Is Falling. -- Barrons.com

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson Sees 2026 Adj EPS $11.43-Adj EPS $11.63 >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Worldwide MedTech Sales $8.80B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: 4Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed and Wound Closure Pdts >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.28-$11.48 >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: See Higher EPS Growth in Second Half of 2026 Vs First Half >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: In 2026, Expect Heavy Investment in 1Q Vs Rest of the Year >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.2% Due to Caplyta >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: With MedTech, Impact of Tariffs Assumed to Be Consistent Throughout 2026 >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Growth Was Partially Offset By Impact From Stelara >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Worldwide Innovative Medicine Sales $15.76B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.4%-6.4% >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q International Sales $10.37B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson Sees 2026 Operational Sales of $99.5B-$100.5B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson Sees 2026 Sales $100B-$101B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q U.S. Sales $14.2B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Sales $24.56B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Orthopaedics Sales $2.44B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Adj EPS $2.46 >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Worldwide Innovative Medicine Sales $15.76B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q EPS $2.10 >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q International Sales $10.37B >JNJ

21 gen 2026, 11:20 UTC

Utili

Johnson & Johnson 4Q Worldwide MedTech Sales $8.8B >JNJ

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

7.49% in crescita

Previsioni per 12 mesi

Media 241.25 USD  7.49%

Alto 265 USD

Basso 217 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

154.93 / 155.895Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

82 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat